|
| Thursday, October 25, 2018 |
|
|
Eisai to Present Latest Data on Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination and Exploratory Research |
| Eisai Co., Ltd. announced today that the latest data regarding its in-house discovered kinase inhibitor lenvatinib mesylate, in combination with Merck & Co.'s anti-PD-1 therapy pembrolizumab, and exploratory research on the STING (stimulator of interferon genes) agonist E7766 as cancer immunotherapy will be presented during the 33rd Annual Meeting of the SITC. more info >> |
|
| Tuesday, October 23, 2018 |
|
|
Eisai: Application Seeking Manufacturing and Marketing Approval in Japan Submitted for Parkinson's Disease Treatment Safinamide |
| Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced that an application seeking manufacturing and marketing approval in Japan was submitted as of today by Meiji for the Parkinson's disease treatment ME2125 (safinamide mesylate, "safinamide"). more info >> |
|
| Monday, October 22, 2018 |
|
|
Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan |
| Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that the two companies have commenced joint medical and marketing activities for tyrosine kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) in Japan. more info >> |
|
| Friday, October 19, 2018 |
|
|
Eisai: Discovery of Candidate Compound as Potential Treatment for Parkinson's Disease Using iPS Cells |
| A joint research group centered around Professor Hideyuki Okano and Associate Professor Jun Kohyama, Department of Physiology of the Keio University School of Medicine, together with a research group of Eisai Co., Ltd. has identified a compound that has the potential to be a treatment for Parkinson's disease by using dopaminergic neurons differentiated from induced pluripotent stem (iPS) cells from patients with familial Parkinson's disease. more info >> |
|
| Thursday, October 18, 2018 |
|
|
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 11th Clinical Trials on Alzheimer's Disease Conference |
| Eisai Co., Ltd. announced today that five oral presentations including a symposium, and two poster presentations. more info >> |
|
| Wednesday, October 17, 2018 |
|
|
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant |
| Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders. more info >> |
|
| Tuesday, October 16, 2018 |
|
|
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Latin America With Eurofarma |
| Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for development and sales in each country. more info >> |
|
| Friday, October 12, 2018 |
|
|
Eisai's New Drug Application for Perampanel for Adjunctive Treatment of Partial Onset Seizures Accepted in China |
| This application for perampanel in partial onset seizures in China was based on the results of three Phase III clinical studies conducted mainly in Europe and the United States, as well as the results of a Phase III clinical study (Study 335) conducted mainly in Asia including China and Japan. more info >> |
|
| Wednesday, October 10, 2018 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2018 Congress |
| At the ESMO 2018 Congress, there will be an oral presentation on tumor growth rate prior to treatment administration and efficacy of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. more info >> |
|
| Friday, October 5, 2018 |
|
|
New Data on Effect of Anti-Obesity Agent BELVIQ on Prevention and Remission of Type 2 Diabetes Presented at The European Association for the Study of Diabetes and Published in The Lancet |
| This new analysis assessed metabolic effects on enrolled patients with T2DM or pre-diabetes (higher than normal blood sugar levels prior to incidence of diabetes) at baseline, as well as patients with normoglycemia. more info >> |
|
|
|
